Equibles

10-Q

ELITE PHARMACEUTICALS INC /NV/ (ELTP)

10-Q 2022-02-14 For: 2021-12-31
View Original
Added on April 06, 2026

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

WASHINGTON,

D.C. 20549

FORM

10-Q

☒

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR

THE QUARTERLY PERIOD ENDED DECEMBER 31, 2021

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR

THE TRANSITION PERIOD FROM _______________ TO _______________

COMMISSION

FILE NUMBER: 001-15697

ELITE PHARMACEUTICALS, INC.
(Exact<br> Name of Registrant as Specified in Its Charter)
nevada 22-3542636
--- ---
(State<br> or other jurisdiction of<br><br> <br>incorporation<br> or organization) (I.R.S.<br> Employer<br><br> <br>Identification<br> No.)
165 LUDLOW AVENUE<br><br> <br>NORTHVALE, new jersey 07647
--- ---
(Address<br> of principal executive offices) (Zip<br> Code)
(201) 750-2646
---
(Registrant’s<br> telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large<br> accelerated filer ☐ Accelerated<br> filer ☐
Non-accelerated<br> filer ☒ Smaller<br> reporting company ☒
Emerging<br> growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title<br> of each class Trading<br> Symbol Name<br> of each exchange on which registered
Common<br> Stock, par value $0.001 per share ELTP OTCQB

Indicate

the number of shares outstanding of each of the issuer’s classes of Common Stock, as of the latest practicable date: shares of 1,011,381,988 Common Stock were issued, and 1,011,281,988 shares of Common Stock were outstanding as of February11, 2022.

Table

of Contents

PAGE
PART<br> I FINANCIAL<br> INFORMATION F-1
ITEM<br> 1. Financial<br> Statements F-1
Condensed<br> Consolidated Balance Sheets as of December31, 2021 (Unaudited) and March 31, 2021 (Audited) F-1
Condensed<br> Consolidated Statement of Operations for the Three and Nine Months Ended December 31, 2021 and 2020 (Unaudited) F-2
Condensed<br> Consolidated Statement of Changes in Shareholders’ Equity for the Three and Nine Months Ended December 31, 2021 and 2020 (Unaudited) F-3
Condensed<br> Consolidated Statement of Cash Flows for the Nine Months Ended December 31, 2021 and 2020 (Unaudited) F-5
Notes<br> to the Unaudited Condensed Consolidated Financial Statements F-6
ITEM<br> 2. Management’s<br> Discussion and Analysis of Financial Condition and Results of Operations 1
ITEM<br> 3. Quantitative<br> and Qualitative Disclosure About Market Risk 8
ITEM<br> 4. Controls<br> and Procedures 8
PART<br> II OTHER<br> INFORMATION 10
ITEM<br> 1. Legal<br> Proceedings 10
ITEM<br> 1A. Risk<br> Factors 10
ITEM<br> 2. Unregistered<br> Sales of Equity Securities and Use of Proceeds 10
ITEM<br> 3. Defaults<br> Upon Senior Securities 10
ITEM<br> 4. Mine<br> Safety Disclosures 10
ITEM<br> 5. Other<br> Information 10
ITEM<br> 6. Exhibits 11
SIGNATURES 12 
| ii |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

CONDENSED

CONSOLIDATED BALANCE SHEETS

PART

I - FINANCIAL INFORMATION

ITEM

  1. FINANCIAL STATEMENTS
March<br> 31, 2021
(Audited)
ASSETS
Current<br> assets:
Cash 7,288,456 $ 3,192,768
Accounts<br> receivable, net of allowance for doubtful accounts of -0-, respectively 2,661,413 3,496,376
Inventory 6,694,070 5,012,902
Prepaid<br> expenses and other current assets 831,074 492,621
Total<br> current assets 17,475,013 12,194,667
Property<br> and equipment, net of accumulated depreciation of 13,051,288 and 12,153,626, respectively 5,986,090 6,649,365
Intangible<br> assets, net of accumulated amortization of -0-, respectively 6,634,035 6,634,035
Operating<br> lease - right-of-use asset 1,082,168 214,674
Other<br> assets:
Restricted<br> cash - debt service for NJEDA bonds 405,027 405,013
Security<br> deposits 364,563 91,738
Total<br> other assets 769,590 496,751
Total<br> assets 31,946,896 $ 26,189,492
LIABILITIES<br> AND SHAREHOLDERS’ EQUITY
Current<br> liabilities:
Accounts<br> payable 1,284,334 $ 929,690
Accrued<br> expenses 4,026,300 4,270,600
Deferred<br> revenue, current portion 13,333 13,333
Bonds<br> payable, current portion, net of bond issuance costs 100,822 95,822
Loans<br> payable, current portion 299,601 314,996
Lease<br> obligation - operating lease, current portion 153,813 188,090
Total<br> current liabilities 5,878,203 5,812,531
Long-term<br> liabilities:
Deferred<br> revenue, net of current portion 35,559 45,558
Bonds<br> payable, net of current portion and bond issuance costs 1,136,303 1,240,668
Loans<br> payable, net of current portion 296,696 500,066
Lease<br> obligation - operating lease, net of current portion 933,542 38,866
Derivative<br> financial instruments - warrants 838,852 2,362,246
Other<br> long-term liabilities 38,187 37,628
Total<br> long-term liabilities 3,279,139 4,225,032
Total<br> liabilities 9,157,342 10,037,563
Shareholders’<br> equity:
Series<br> J convertible preferred stock; par value of 0.01; 50 shares authorized; 0 issued and outstanding as of December 31, 2021 and March<br> 31, 2021 — —
Common<br> Stock; par value 0.001; 1,445,000,000 shares authorized; 1,011,381,988 shares issued and 1,011,281,988 shares outstanding as of<br> December 31, 2021; 1,009,276,752 shares issued and 1,009,176,752 shares outstanding as of March 31, 2021 1,011,385 1,009,279
Additional<br> paid-in capital 164,573,491 164,407,480
Treasury<br> stock; 100,000 shares as of December 31, 2021 and March 31, 2021; at cost (306,841 ) (306,841 )
Accumulated<br> deficit (142,488,481 ) (148,957,989 )
Total<br> shareholders’ equity 22,789,554 16,151,929
Total<br> liabilities and shareholders’ equity 31,946,896 $ 26,189,492

All values are in US Dollars.

The

accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

| F-1 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

CONDENSED

CONSOLIDATED STATEMENT OF OPERATIONS

(UNAUDITED)

2021 2020 2021 2020
For<br> the Three Months Ended December 31, For<br> the Nine Months Ended December 31,
2021 2020 2021 2020
Revenue:
Manufacturing<br> fees 7,667,674 $ 4,849,871 $ 20,639,421 $ 17,659,834
Licensing<br> fees 1,307,140 1,196,711 3,950,623 3,325,384
Total<br> revenue 8,974,814 6,046,582 24,590,044 20,985,218
Cost<br> of manufacturing 4,957,150 2,643,175 13,209,430 10,984,021
Gross<br> profit 4,017,664 3,403,407 11,380,614 10,001,197
Operating<br> expenses:
Research<br> and development 956,628 1,245,669 3,312,540 3,337,287
General<br> and administrative 929,547 826,019 2,930,126 2,491,762
Non-cash<br> compensation through issuance of stock options 3,630 1,651 10,617 9,261
Depreciation<br> and amortization 296,559 328,899 908,297 990,861
Total<br> operating expenses 2,186,364 2,402,238 7,161,580 6,829,171
Income<br> from operations 1,831,300 1,001,169 4,219,034 3,172,026
Other<br> income, net:
Change<br> in fair value of derivative instruments 489,500 1,083,566 1,523,394 1,645,042
Interest<br> expense and amortization of debt issuance costs (37,400 ) (79,673 ) (126,376 ) (238,857 )
Gain<br> on sale of fixed assets — 6,973 — 48,463
Interest<br> income 13 98 77 463
Other<br> income, net 452,113 1,010,964 1,397,095 1,455,111
Income<br> from operations before income taxes 2,283,413 2,012,133 5,616,129 4,627,137
Income<br> tax expense — — (4,000 ) (2,500 )
Net<br> benefit for sale of state net operating losses and credits — — 857,379 946,407
Net<br> income attributable to common shareholders $ 2,283,413 $ 2,012,133 $ 6,469,508 $ 5,571,044
Basic<br> net income per share attributable to common shareholders $ 0.00 $ 0.00 $ 0.01 $ 0.01
Diluted<br> net income per share attributable to common shareholders $ 0.00 $ 0.00 $ 0.00 $ 0.01
Basic<br> weighted average Common Stock outstanding 1,011,281,988 1,009,176,752 1,010,416,823 921,339,333
Diluted<br> weighted average Common Stock outstanding 1,011,281,988 1,009,176,752 1,010,416,823 921,339,333

The accompanying notes are an integral part ofthese unaudited condensed consolidated financial statements.

| F-2 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

CONDENSED

CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

Shares Amount Shares Amount Capital Shares Amount Deficit Equity
Series<br> J Preferred Stock Common Stock Additional<br><br> <br>Paid-In Treasury<br> Stock Accumulated Total Shareholders’
Shares Amount Shares Amount Capital Shares Amount Deficit Equity
Balance as of March 31, 2021 — $ — 1,009,276,752 $ 1,009,279 $ 164,407,480 100,000 $ (306,841 ) $ (148,957,989 ) $ 16,151,929
Net income — — — — — — — 2,389,118 2,389,118
Conversion of Preferred Stock to Common Stock
Conversion of Preferred Stock to Common Stock, shares
Initial commitment shares issued pursuant to the 2020 Lincoln Park purchase<br> agreement
Initial commitment shares issued pursuant to the 2020 Lincoln Park purchase<br> agreement, shares
Common Stock sold pursuant to the 2020 Lincoln Park purchase agreement
Common Stock sold pursuant to the 2020 Lincoln Park purchase<br> agreement, shares
Common Stock issued as additional commitment shares pursuant to the 2020<br> Lincoln Park purchase agreement
Common Stock issued as additional commitment shares pursuant to the 2020<br> Lincoln Park purchase agreement, shares
Costs associated with raising capital
Shares issued in payment of Director fees
Shares issued in payment of Director fees, shares
Shares issued in payment of consulting expenses
Shares issued in payment of consulting expenses, shares
Non-cash compensation through the issuance of employee<br> stock options — — — — 2,811 — — — 2,811
Shares issued in payment of salaries — — 2,105,236 2,106 155,394 — — — 157,500
Balance at June 30, 2021 — $ — 1,011,381,988 $ 1,011,385 $ 164,565,685 100,000 $ (306,841 ) $ (146,568,871 ) $ 18,701,358
Net income — $ — — $ — $ — — $ — $ 1,796,977 1,796,977
Non-cash compensation through the issuance of employee<br> stock options — — — — 4,176 — — — 4,176
Balance at September 30, 2021 — $ — 1,011,381,988 $ 1,011,385 $ 164,569,861 100,000 $ (306,841 ) $ (144,771,894 ) $ 20,502,511
Net income — $ — — $ — $ — — $ — $ 2,283,413 $ 2,283,413
Non-cash compensation through the issuance of employee<br> stock options — $ — — $ — $ 3,630 — $ — $ — $ 3,630
Balance at December 31, 2021 — $ — 1,011,381,988 $ 1,011,385 $ 164,573,491 100,000 $ (306,841 ) $ (142,488,481 ) $ 22,789,554

The accompanying notes are an integral part of

these unaudited condensed consolidated financial statements.

| F-3 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

CONDENSED

CONSOLIDATED STATEMENT OF SHAREHOLDERS’ EQUITY

(UNAUDITED)

(continued) Series J<br><br> <br>Preferred Stock Common<br> Stock Additional Paid-In Treasury<br> Stock Accumulated Total Shareholders’
Shares Amount Shares Amount Capital Shares Amount Deficit Equity
Balance as of March 31, 2020 24 $ 13,903,960 840,504,367 $ 840,507 $ 150,264,605 100,000 $ (306,841 ) $ (154,046,410 ) $ 10,655,821
Net income — — — — — — — 1,077,349 1,077,349
Non-cash compensation through the issuance of employee stock options — — — — 5,521 — — — 5,521
Shares issued in payment of salaries — $ — 574,597 $ 574 $ 49,426 — $ — $ — 50,000
Balance at June 30, 2020 24 $ 13,903,960 841,078,964 $ 841,081 $ 150,319,552 100,000 $ (306,841 ) $ (152,969,061 ) $ 11,788,691
Net income — — — — — — — 2,481,562 2,481,562
Conversion of Preferred Stock to Common Stock (24 ) (13,903,960 ) 158,017,321 158,017 13,745,943 — — — —
Initial commitment shares issued pursuant to the 2020 Lincoln Park purchase<br> agreement — — 5,975,857 5,976 463,129 — — — 469,105
Common Stock sold pursuant to the 2020 Lincoln Park purchase agreement — — 640,543 641 41,582 — — — 42,223
Common Stock issued as additional commitment shares pursuant to the 2020<br> Lincoln Park purchase agreement — — 10,094 10 722 — — — 732
Costs associated with raising capital — — — — (469,837 ) — — — (469,837 )
Non-cash compensation through the issuance of employee stock options — — — — 2,089 — — — 2,089
Shares issued in payment of Director fees — — 1,550,343 1,551 133,449 — — — 135,000
Shares issued in payment of salaries — — 71,739 71 6,179 — — — 6,250
Shares issued in payment of consulting expenses — — 1,931,891 1,932 159,101 — — — 161,033
Balance at September 30, 2020 — $ — 1,009,276,752 $ 1,009,279 $ 164,401,909 100,000 $ (306,841 ) $ (150,487,499 ) $ 14,616,848
Net income — $ — — $ — $ — — $ — $ 2,012,133 $ 2,012,133
Non-cash compensation through the issuance of employee stock options — $ — — $ — $ 1,651 — $ — $ — $ 1,651
Balance at December 31, 2020 — $ — 1,009,276,752 $ 1,009,279 $ 164,403,560 100,000 $ (306,841 ) $ (148,475,366 ) $ 16,630,632

The

accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

| F-4 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

CONDENSED

CONSOLIDATED STATEMENT OF CASH FLOWS

(UNAUDITED)

2021 2020
For<br> the Nine Months Ended December 31,
2021 2020
CASH<br> FLOWS FROM OPERATING ACTIVITIES:
Net<br> income $ 6,469,508 $ 5,571,044
Adjustments<br> to reconcile net income to net cash provided by operating activities:
Depreciation<br> and amortization 908,297 990,861
Amortization<br> of operating leases - right-of-use assets 175,306 150,897
Gain<br> on the disposal of property and equipment — (48,463 )
Change<br> in fair value of derivative financial instruments - warrants (1,523,394 ) (1,645,042 )
Non-cash<br> compensation accrued 641,664 676,740
Non-cash<br> compensation through the issuance of employee stock options 10,617 9,261
Non-cash<br> rent expense and lease accretion 559 1,626
Change<br> in operating assets and liabilities:
Accounts<br> receivable 834,963 810,639
Inventory (1,681,168 ) (659,535 )
Prepaid<br> expenses and other current assets (367,154 ) (173,142 )
Accounts<br> payable, accrued expenses and other current liabilities (373,820 ) (1,417,530 )
Deferred<br> revenue and customer deposits (9,999 ) (170,000 )
Lease<br> obligations - operating leases (182,401 ) (154,127 )
Net<br> cash provided by operating activities 4,902,978 3,943,229
CASH<br> FLOWS FROM INVESTING ACTIVITIES:
Purchase<br> of property and equipment (234,387 ) (145,079 )
Proceeds<br> from disposal of property and equipment — 67,200
Net<br> cash used in investing activities (234,387 ) (77,879 )
CASH<br> FLOWS FROM FINANCING ACTIVITIES:
Payment<br> of bond principal (110,000 ) (105,000 )
Other<br> loan payments (462,889 ) (534,793 )
Proceeds<br> from the issuance of Common Stock — 42,223
Other<br> loan proceeds — 1,013,480
Net<br> cash (used in) provided by financing activities (572,889 ) 415,910
Net<br> change in cash and restricted cash 4,095,702 4,281,260
Cash<br> and restricted cash, beginning of period 3,597,781 1,536,530
Cash<br> and restricted cash, end of period $ 7,693,483 $ 5,817,790
Supplemental<br> disclosure of cash and non-cash transactions:
Cash<br> paid for interest $ 126,376 $ 239,940
Financing<br> of equipment purchases and insurance renewal $ 244,124 $ 410,141
Stock<br> issued in payment of Directors fees, salaries and consulting expenses $ 157,500 $ 352,283
Supplemental<br> non-cash amounts of lease liabilities arising from obtaining right of use assets $ 1,042,800 $ —
Commitment<br> shares issued to Lincoln Park Capital $ — $ 469,837
Conversion<br> of preferred stock to Common Stock $ — $ 13,903,960

The

accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

| F-5 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE

  1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Overview

Elite Pharmaceuticals, Inc. (the “Company” or “Elite”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly owned subsidiary Elite Laboratories, Inc. (“Elite Labs”) was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada. Elite Labs engages primarily in researching, developing, licensing and manufacture of generic, oral dose pharmaceuticals. The Company is equipped to manufacture controlled-release products on a contract basis for third parties and itself, if and when the products are approved. These products include drugs that cover therapeutic areas for allergy, bariatric, attention deficit and infection. Research and development activities are performed with an objective of developing products that will secure marketing approvals from the United States Food and Drug Administration (“FDA”), and thereafter, commercially exploiting such products.

Principlesof Consolidation

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). The unaudited condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary, Elite Labs. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements reflect all adjustments, consisting of normal recurring items, which are, in the opinion of management, necessary for a fair presentation of such statements. The results of operations for the three and nine months ended December 31, 2021 are not necessarily indicative of the results that may be expected for the entire year.

SegmentInformation

Financial Accounting Standards Board (“FASB”) Accounting Standards Codification 280 (“ASC 280”), Segment Reporting, establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance.

The Company’s chief operating decision maker is the Chief Executive Officer, who reviews the financial performance and the results of operations of the segments prepared in accordance with GAAP when making decisions about allocating resources and assessing performance of the Company.

The Company has determined that its reportable segments are products whose marketing approvals were secured via an Abbreviated New Drug Applications (“ANDA”) and products whose marketing approvals were secured via a New Drug Application (“NDA”). ANDA products are referred to as generic pharmaceuticals and NDA products are referred to as branded pharmaceuticals.

There are currently no intersegment revenues. Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s condensed unaudited consolidated financial statements. Please see Note 15 for further details.

RevenueRecognition

The Company generates revenue primarily from manufacturing and licensing fees. Manufacturing fees include the development of pain management products, manufacturing of a line of generic pharmaceutical products with approved ANDA, through the manufacture of formulations and the development of new products. Licensing fees include the commercialization of products either by license and the collection of royalties, or the expansion of licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations.

| F-6 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Under ASC 606, Revenue from Contacts with Customers (“ASC 606”), the Company recognizes revenue when the customer obtains control of promised goods or services, in an amount that reflects the consideration which is expected to be received in exchange for those goods or services. The Company recognizes revenues following the five-step model prescribed under ASC 606: (i) identify contract(s) with a customer; (ii) identify the performance obligation(s) in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation(s) in the contract; and (v) recognize revenues when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied. Sales, value add, and other taxes collected on behalf of third parties are excluded from revenue.

Natureof goods and services

The following is a description of the Company’s goods and services from which the Company generates revenue, as well as the nature, timing of satisfaction of performance obligations, and significant payment terms for each, as applicable:

a) Manufacturing Fees

The Company is equipped to manufacture controlled-release products on a contract basis for third parties, if, and when, the products are approved. These products include products using controlled-release drug technology. The Company also develops and markets (either on its own or by license to other companies) generic and proprietary controlled-release pharmaceutical products.

The Company recognizes revenue when the customer obtains control of the Company’s product based on the contractual shipping terms of the contract. The Company is primarily responsible for fulfilling the promise to provide the product, is responsible to ensure that the product is produced in accordance with the related supply agreement and bears risk of loss while the inventory is in-transit to the commercial partner. Revenue is measured as the amount of consideration the Company expects to receive in exchange for transferring products to a customer.

b) License Fees

The Company enters into licensing and development agreements, which may include multiple revenue generating activities, including milestones payments, licensing fees, product sales and services. The Company analyzes each element of its licensing and development agreements in accordance with ASC 606 to determine appropriate revenue recognition. The terms of the license agreement may include payment to the Company of licensing fees, non-refundable upfront license fees, milestone payments if specified objectives are achieved, and/or royalties on product sales.

If the contract contains a single performance obligation, the entire transaction price is allocated to the single performance obligation. Contracts that contain multiple performance obligations require an allocation of the transaction price based on the estimated relative standalone selling prices of the promised products or services underlying each performance obligation. The Company determines standalone selling prices based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as market conditions and internally approved pricing guidelines related to the performance obligations.

The Company recognizes revenue from non-refundable upfront payments at a point in time, typically upon fulfilling the delivery of the associated intellectual property to the customer. For those milestone payments which are contingent on the occurrence of particular future events (for example, payments due upon a product receiving FDA approval), the Company determined that these need to be considered for inclusion in the calculation of total consideration from the contract as a component of variable consideration using the most-likely amount method. As such, the Company assesses each milestone to determine the probability and substance behind achieving each milestone. Given the inherent uncertainty of the occurrence of future events, the Company will recognize revenue from the milestone when there is not a high probability of a reversal of revenue, which typically occurs near or upon achievement of the event.

| F-7 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Significant management judgment is required to determine the level of effort required under an arrangement and the period over which the Company expects to complete its performance obligations under the arrangement. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method.

When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC 606-10-32-18, the Company does not assess whether a significant financing component exists if the period between when the Company performs its obligations under the contract and when the customer pays is one year or less. None of the Company’s contracts contained a significant financing component as of December 31, 2021.

In accordance with ASC 606-10-55-65, royalties are recognized when the subsequent sale of the customer’s products occurs.

The Company entered into a sales and distribution licensing agreement with Epic Pharma LLC, (“Epic”) dated June 4, 2015 (the “2015 Epic License Agreement”), which has been determined to satisfy the criteria for consideration as a collaborative agreement and is accounted for accordingly. The 2015 Epic License Agreement expired on June 4, 2020 without renewal.

The Company entered into a Master Development and License Agreement with SunGen Pharma LLC dated August 24, 2016 (the “SunGen Agreement”), which has been determined to satisfy the criteria for consideration as a collaborative agreement and is accounted for accordingly. On April 3, 2020, Elite and SunGen mutually agreed to discontinue any further joint product development activities.

Disaggregationof revenue

In the following table, revenue is disaggregated by type of revenue generated by the Company. The table also includes a reconciliation of the disaggregated revenue with the reportable segments:

SCHEDULE

OF DISAGGREGATION OF REVENUE

For<br> the Three Months Ended December 31, For<br> the Nine Months Ended December 31,
2021 2020 2021 2020
NDA:
Manufacturing<br> fees $ 7,667,674 $ 4,849,871 $ 20,639,421 $ 17,659,834
Licensing<br> fees $ — $ — $ — $ 166,167
Total<br> NDA revenue — — — 166,167
ANDA:
Manufacturing<br> fees $ 7,667,674 $ 4,849,871 $ 20,639,421 $ 17,659,834
Licensing<br> fees 1,307,140 1,196,711 3,950,623 3,159,217
Total<br> ANDA revenue 8,974,814 6,046,582 24,590,044 20,819,051
Total<br> revenue $ 8,974,814 $ 6,046,582 $ 24,590,044 $ 20,985,218

Selected information on reportable segments and reconciliation of operating income by segment to income (loss) from operations before income taxes are disclosed within Note 15.

| F-8 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Cash

The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks and money market instruments. The Company places its cash and cash equivalents with high-quality, U.S. financial institutions and, to date has not experienced losses on any of its balances.

RestrictedCash

As

of December 31, 2021, and March 31, 2021, the Company had $405,027 and $405,013 of restricted cash, respectively, related to debt service reserve in regard to the New Jersey Economic Development Authority (“NJEDA”) bonds (see Note 5).

AccountsReceivable

Accounts receivable are comprised of balances due from customers, net of estimated allowances for uncollectible accounts. In determining collectability, historical trends are evaluated, and specific customer issues are reviewed on a periodic basis to arrive at appropriate allowances.

Inventory

Inventory is recorded at the lower of cost or market on specific identification by lot number basis.

Long-LivedAssets

The Company periodically evaluates the fair value of long-lived assets, which include property and equipment and intangibles, whenever events or changes in circumstances indicate that its carrying amounts may not be recoverable.

Property and equipment are stated at cost. Depreciation is provided on the straight-line method based on the estimated useful lives of the respective assets which range from three to forty years. Major repairs or improvements are capitalized. Minor replacements and maintenance and repairs which do not improve or extend asset lives are expensed currently.

Upon retirement or other disposition of assets, the cost and related accumulated depreciation are removed from the accounts and the resulting gain or loss, if any, is recognized in income.

IntangibleAssets

The Company capitalizes certain costs to acquire intangible assets; if such assets are determined to have a finite useful life they are amortized on a straight-line basis over the estimated useful life. Costs to acquire indefinite lived intangible assets, such as costs related to ANDAs are capitalized accordingly.

The Company tests its intangible assets for impairment at least annually (as of March 31st) and whenever events or circumstances change that indicate impairment may have occurred. A significant amount of judgment is involved in determining if an indicator of impairment has occurred. Such indicators may include, among others and without limitation: a significant decline in the Company’s expected future cash flows; a sustained, significant decline in the Company’s stock price and market capitalization; a significant adverse change in legal factors or in the business climate of the Company’s segments; unanticipated competition; and slower growth rates.

As of December 31, 2021, the Company did not identify any indicators of impairment.

Please also see Note 4 for further details on intangible assets.

| F-9 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Researchand Development

Research and development expenditures are charged to expense as incurred.

Contingencies

Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.

IncomeTaxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates in effect for the year in which those temporary differences are expected to be recovered or settled. Where applicable, the Company records a valuation allowance to reduce any deferred tax assets that it determines will not be realizable in the future.

The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on income tax returns it files if such tax position is more likely than not to be sustained on examination by the taxing authorities, based on the technical merits of the position. These tax benefits are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate resolution.

The Company operates in multiple tax jurisdictions within the United States of America. The Company remains subject to examination in all tax jurisdiction until the applicable statutes of limitation expire. As of December 31, 2021, a summary of the tax years that remain subject to examination in our major tax jurisdictions are: United States – Federal, 2016 and forward, and State, 2013 and forward. The Company did not record unrecognized tax positions for the three and nine months ended December 31, 2021 and 2020.

Warrantsand Preferred Shares

The accounting treatment of warrants and preferred share series issued is determined pursuant to the guidance provided by ASC 470, Debt, ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging, as applicable. Each feature of a freestanding financial instrument including, without limitation, any rights relating to subsequent dilutive issuances, dividend issuances, equity sales, rights offerings, forced conversions, optional redemptions, automatic monthly conversions, dividends and exercise is assessed with determinations made regarding the proper classification in the Company’s financial statements.

Stock-BasedCompensation

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation-Stock Compensation. Under the fair value recognition provisions, stock-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as an expense on a straight-line basis over the requisite service period, based on the terms of the awards. The cost of the stock-based payments to nonemployees that are fully vested and non-forfeitable as at the grant date is measured and recognized at that date, unless there is a contractual term for services in which case such compensation would be amortized over the contractual term.

| F-10 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

In accordance with the Company’s Director compensation policy and certain employment contracts, director’s fees and a portion of employee’s salaries are to be paid via the issuance of shares of the Company’s Common Stock (“Common Stock”), in lieu of cash, with the valuation of such share being calculated on a quarterly basis and equal to the average closing price of the Company’s Common Stock.

EarningsPer Share Attributable to Common Shareholders’

The Company follows ASC 260, Earnings Per Share, which requires presentation of basic and diluted earnings per share (“EPS”) on the face of the income statement for all entities with complex capital structures and requires a reconciliation of the numerator and denominator of the basic EPS computation to the numerator and denominator of the diluted EPS computation. In the accompanying financial statements, basic earnings per share is computed by dividing net income by the weighted average number of shares of Common Stock outstanding during the period. The computation of diluted net income per share does not include the conversion of securities that would have an antidilutive effect.

The following is the computation of earnings per share applicable to common shareholders for the periods indicated:

SCHEDULE

OF EARNINGS (LOSS) PER SHARE APPLICABLE TO COMMON SHAREHOLDERS

2021 2020 2021 2020
For<br> the Three Months Ended December 31, For<br> the Nine Months Ended December 31,
2021 2020 2021 2020
Numerator
Net<br> income - basic $ 2,283,413 $ 2,012,133 $ 6,469,508 $ 5,571,044
Effect<br> of dilutive instrument on net income (489,500 ) — (1,523,394 ) —
Net<br> income - diluted $ 1,793,913 $ 2,012,133 $ 4,946,114 $ 5,571,044
Denominator
Weighted average<br> shares of Common Stock outstanding - basic 1,011,281,988 1,009,176,752 1,010,416,823 921,339,333
Dilutive<br> effect of stock options and convertible securities — — — —
Weighted<br> average shares of Common Stock outstanding - diluted 1,011,281,988 1,009,176,752 1,010,416,823 921,339,333
Net income per share
Basic $ 0.00 $ 0.00 $ 0.01 $ 0.01
Diluted $ 0.00 $ 0.00 $ 0.00 $ 0.01

FairValue of Financial Instruments

ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) provides a framework for measuring fair value in accordance with generally accepted accounting principles.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs).

| F-11 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy under ASC 820 are described as follows:

● Level<br> 1 – Unadjusted quoted prices in active markets for identical assets or liabilities<br> that are accessible at the measurement date.
● Level<br> 2 – Inputs other than quoted prices included within Level 1 that are observable for<br> the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices<br> for similar assets or liabilities in active markets; quoted prices for identical or similar<br> assets or liabilities in markets that are not active; inputs other than quoted prices that<br> are observable for the asset or liability; and inputs that are derived principally from or<br> corroborated by observable market data by correlation or other means.
● Level<br> 3 – Inputs that are unobservable for the asset or liability.

Measuredon a Recurring Basis

The following table presents information about our liabilities measured at fair value on a recurring basis, aggregated by the level in the fair value hierarchy within which those measurements fell:

SCHEDULE

OF LIABILITIES MEASURED AT FAIR VALUE ON A RECURRING BASIS

Fair<br> Value Measurement Using
Amount<br> at Fair Value Level<br> 1 Level<br> 2 Level<br> 3
December<br> 31, 2021
Liabilities
Derivative<br> financial instruments - warrants $ 838,852 $ — $ — $ 838,852
March<br> 31, 2021
Liabilities
Derivative<br> financial instruments - warrants $ 2,362,246 $ — $ — $ 2,362,246

See Note 11, for specific inputs used in determining fair value.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts receivable, prepaid expenses and other current assets, accounts payable and accrued expenses, approximate their fair values because of the short maturity of these instruments. Based upon current borrowing rates with similar maturities the carrying value of long-term debt approximates fair value.

Non-FinancialAssets that are Measured at Fair Value on a Non-Recurring Basis

Non-financial assets such as intangible assets, and property and equipment are measured at fair value only when an impairment loss is recognized. The Company did not record an impairment charge related to these assets in the periods presented.

TreasuryStock

The Company records treasury stock at the cost to acquire it and includes treasury stock as a component of shareholders’ equity.

RecentlyIssued Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on FinancialInstruments. This update requires immediate recognition of management’s estimates of current expected credit losses (“CECL”). Under the prior model, losses were recognized only as they were incurred. The new model is applicable to all financial instruments that are not accounted for at fair value through net income. The standard is effective for fiscal years beginning after December 15, 2022 for public entities qualifying as smaller reporting companies. Early adoption is permitted. The Company is currently assessing the impact of this update on the consolidated financial statements and does not expect a material impact on the consolidated financial statements.

| F-12 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Management has evaluated other recently issued accounting pronouncements and does not believe that any of these pronouncements will have a significant impact on our consolidated financial statements and related disclosures.

NOTE

  1. INVENTORY

Inventory consisted of the following:

SCHEDULE

OF INVENTORY

December<br> 31, 2021 March<br> 31, 2021
Finished<br> goods $ 579,336 $ 274,603
Work-in-progress 966 781,350
Raw<br> materials 6,113,768 3,956,949
Inventory,<br> net $ 6,694,070 $ 5,012,902

NOTE

  1. PROPERTY AND EQUIPMENT, NET

Property and equipment consisted of the following:

SCHEDULE

OF PROPERTY AND EQUIPMENT

December<br> 31, 2021 March<br> 31, 2021
Land,<br> building and improvements $ 5,456,523 $ 5,456,523
Laboratory,<br> manufacturing, warehouse and transportation equipment 12,753,553 12,580,457
Office<br> equipment and software 373,601 373,601
Furniture<br> and fixtures 453,701 392,410
19,037,378 18,802,991
Less:<br> Accumulated depreciation (13,051,288 ) (12,153,626 )
$ 5,986,090 $ 6,649,365

Depreciation

expense was $293,014 and $505,987 for the three months ended, and $897,662 and $980,227 for the nine months ended December 31, 2021 and 2020, respectively.

NOTE

  1. INTANGIBLE ASSETS

The

following table summarizes the Company’s intangible assets: SCHEDULE OF INTANGIBLE ASSETS

December<br> 31, 2021
Estimated<br> Useful Life Gross<br> Carrying Amount Additions Reductions Accumulated<br> Amortization Net<br> Book Value
Patent<br> application costs * $ 465,684 $ — $ — $ — $ 465,684
ANDA<br> acquisition costs Indefinite 6,168,351 — — — 6,168,351
$ 6,634,035 $ — $ — $ — $ 6,634,035
March<br> 31, 2021
--- --- --- --- --- --- --- --- --- --- --- ---
Estimated<br> Useful Life Gross<br> Carrying Amount Additions Reductions Accumulated<br> Amortization Net<br> Book Value
Patent<br> application costs * $ 465,684 $ — $ — $ — $ 465,684
ANDA<br> acquisition costs Indefinite 6,168,351 — — — 6,168,351
$ 6,634,035 $ — $ — $ — $ 6,634,035 
| F-13 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

* Patent<br> application costs were incurred in relation to the Company’s abuse deterrent opioid<br> technology. Amortization of the patent costs will begin upon the issuance of marketing authorization<br> by the FDA. Amortization will then be calculated on a straight-line basis through the expiry<br> of the related patent(s).

NOTE

  1. NJEDA BONDS

During August 2005, the Company refinanced a bond issue occurring in 1999 through the issuance of Series A and B Notes tax-exempt bonds (the “NJEDA Bonds” and/or “Bonds”). During July 2014, the Company retired all outstanding Series B Notes, at par, along with all accrued interest due and owed.

In

relation to the Series A Notes, the Company is required to maintain a debt service reserve. The debt service reserve is classified as restricted cash on the accompanying unaudited condensed consolidated balance sheets. The NJEDA Bonds require the Company to make an annual principal payment on September 1st based on the amount specified in the loan documents and semi-annual interest payments on March 1st and September 1st, equal to interest due on the outstanding principal. The annual interest rate on the Series A Note is 6.5%. The NJEDA Bonds are collateralized by a first lien on the Company’s facility and equipment acquired with the proceeds of the original and refinanced bonds.

The following tables summarize the Company’s bonds payable liability:

SCHEDULE

OF BONDS PAYABLE LIABILITY

December<br> 31, 2021 March<br> 31, 2021
Gross<br> bonds payable
NJEDA<br> Bonds - Series A Notes $ 1,360,000 $ 1,470,000
Less:<br> Current portion of bonds payable (prior to deduction of bond offering costs) (115,000 ) (110,000 )
Long-term<br> portion of bonds payable (prior to deduction of bond offering costs) $ 1,245,000 $ 1,360,000
Bond<br> offering costs $ 354,454 $ 354,454
Less:<br> Accumulated amortization (231,579 ) (220,944 )
Bond<br> offering costs, net $ 122,875 $ 133,510
Current<br> portion of bonds payable - net of bond offering costs
Current<br> portions of bonds payable $ 115,000 $ 110,000
Less:<br> Bonds offering costs to be amortized in the next 12 months (14,178 ) (14,178 )
Current<br> portion of bonds payable, net of bond offering costs $ 100,822 $ 95,822
Long<br> term portion of bonds payable - net of bond offering costs
Long<br> term portion of bonds payable 1,245,000 $ 1,360,000
Less:<br> Bond offering costs to be amortized subsequent to the next 12 months (108,697 ) (119,332 )
Long<br> term portion of bonds payable, net of bond offering costs $ 1,136,303 $ 1,240,668

Amortization

expense was $3,545 and $3,544 for the three months ended, and $10,635 and $10,634 for the nine months ended December 31, 2021 and 2020, respectively. As of December 31, 2021 and March 31, 2021, interest payable was $29,467 and $7,963, respectively.

| F-14 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE

  1. LOANS PAYABLE

Loans payable consisted of the following:

SCHEDULE OF LOANS PAYABLE

December<br> 31, 2021 March<br> 31, 2021
Equipment<br> and insurance financing loans payable, between 3.5% and 12.73% interest and maturing between December 2021 and October 2025 $ 596,297 $ 815,062
Less:<br> Current portion of loans payable (299,601 ) (314,996 )
Long-term<br> portion of loans payable $ 296,696 $ 500,066

The

interest expense associated with the loans payable was $14,692 and $19,422 for the three months ended, and $50,290 and $58,062 for the nine months ended December 31, 2021 and 2020, respectively.

NOTE

  1. RELATED PARTY SECURED PROMISSORY NOTE WITH MIKAH PHARMA, LLC

For

consideration of the assets acquired on May 15, 2017, the Company issued a Secured Promissory Note (the “Mikah Note”) to Mikah Pharma, LLC (“Mikah”) for the principal sum of $1,200,000. Mikah was founded in 2009 by Nasrat Hakim (“Hakim”), a related party and the Company’s President, Chief Executive Officer and Chairman of the Board. The Mikah Note matured on December 31, 2020 and was retired at par in March 2021. The principal amount of $1,200,000 was repaid by the Company at maturity.

Interest

expense associated with the Note was $30,000 for the three months ended and $90,000 for the nine months ended December 31, 2020. A total of $435,000 in accrued interest expense, representing interest expense accrued during the life of the Mikah Note, was due and owing as of the maturity date of the Mikah Note. Of the $435,000 accrued interest due at maturity, $435,000 of accrued interest was satisfied by offset against amounts due from Mikah pursuant to the development agreement between the Company and Mikah, dated December 3, 2018 (see Note 16).

NOTE

  1. DEFERRED REVENUE

Deferred revenues in the aggregate amount of $48,892 as of December 31, 2021, were comprised of a current component of $13,333 and a long-term component of $35,559. Deferred revenues in the aggregate amount of $58,891 as of March 31, 2021, were comprised of a current component of $13,333 and a long-term component of $45,558. These line items represent the unamortized amounts of a $200,000 advance payment received for a TAGI Pharma (“TAGI”) licensing agreement with a fifteen-year term beginning in September 2010 and ending in August 2025 and the $5,000,000 advance payment Epic Collaborative Agreement with a five-year term beginning in June 2015 and ending in May 2020. These advance payments were recorded as deferred revenue when received and are earned, on a straight-line basis over the life of the licenses. The current component is equal to the amount of revenue to be earned during the 12-month period immediately subsequent to the balance sheet date and the long-term component is equal to the amount of revenue to be earned thereafter.

NOTE

  1. COMMITMENTS AND CONTINGENCIES

Occasionally, the Company may be involved in claims and legal proceedings arising from the ordinary course of its business. The Company records a provision for a liability when it believes that it is both probable that a liability has been incurred, and the amount can be reasonably estimated. If these estimates and assumptions change or prove to be incorrect, it could have a material impact on the Company’s condensed consolidated financial statements. Contingencies are inherently unpredictable, and the assessments of the value can involve a series of complex judgments about future events and can rely heavily on estimates and assumptions.

OperatingLeases – 135 Ludlow Ave.

The

Company entered into an operating lease for a portion of a one-story warehouse, located at 135 Ludlow Avenue, Northvale, New Jersey (the “135 Ludlow Ave. lease”). The 135 Ludlow Ave. lease is for approximately 15,000 square feet of floor space and began on July 1, 2010. During July 2014, the Company modified the 135 Ludlow Ave. lease in which the Company was permitted to occupy the entire 35,000 square feet of floor space in the building (“135 Ludlow Ave. modified lease”).

| F-15 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The 135 Ludlow Ave. modified lease includes an initial term, which expired on December 31, 2016 with two tenant renewal options of five years each, at the sole discretion of the Company. On June 22, 2016, the Company exercised the first of these renewal options, with such option including a term that begins on January 1, 2017 and expires on December 31, 2021. On June 30, 2021, the Company exercised the second of the renewal options, with such option including a term that begins on January 1, 2022 and expires on December 31, 2026.

The 135 Ludlow Ave. modified lease property required significant leasehold improvements and qualifications, as a prerequisite, for its intended future use. Manufacturing, packaging, warehousing and regulatory activities are currently conducted at this location. Additional renovations and construction to further expand the Company’s manufacturing resources are in progress.

In October 2020, the Company entered into an operating lease for office space in Pompano Beach, Florida (the “Pompano Office Lease”). The Pompano Office Lease is for approximately 1,275 square feet of office space, with Elite taking occupancy on November 1, 2020. The Pompano Office includes a 3-month abatement from November 2020 through February 2021 and has a term of three years, ending on October 31, 2023.

The Company assesses whether an arrangement is a lease or contains a lease at inception. For arrangements considered leases or that contain a lease that is accounted for separately, the Company determines the classification and initial measurement of the right-of-use asset and lease liability at the lease commencement date, which is the date that the underlying asset becomes available for use. The Company has elected to account for non-lease components associated with its leases and lease components as a single lease component.

The Company recognizes a right-of-use asset, which represents the Company’s right to use the underlying asset for the lease term, and a lease liability, which represents the present value of the Company’s obligation to make payments arising over the lease term. The present value of the lease payments is calculated using either the implicit interest rate in the lease or an incremental borrowing rate.

Lease assets and liabilities are classified as follows on the condensed consolidated balance sheet:

SCHEDULE OF LEASE ASSETS AND LIABILITIES

Lease Classification As<br> of December 31, 2021
Assets
Operating Operating<br> lease – right-of-use asset $ 1,082,168
Total<br> leased assets $ 1,082,168
Liabilities
Current
Operating Lease<br> obligation – operating lease $ 153,813
Long-term
Operating Lease<br> obligation – operating lease, net of current portion 933,542
Total<br> lease liabilities $ 1,087,355

Rent

expense is recorded on the straight-line basis. Rent expense under the 135 Ludlow Ave. modified lease for the three months ended December 31, 2021 and 2020 was $57,105 and $55,986, respectively, and $171,315 and $167,958 for the nine months ended December 31, 2021 and 2020, respectively. Rent expense under the Pompano Office Lease for the three and nine months ended December 31, 2021 was $6,144 and $17,688, respectively. There was no rent expense under the Pompano Office lease for the three and nine months ended December 31, 2020 as there was a rent abatement period from November 2020 through February 2021. Rent expense is recorded in general and administrative expense in the unaudited condensed consolidated statements of operations.

| F-16 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The table below shows the future minimum rental payments, exclusive of taxes, insurance and other costs, under the 135 Ludlow Ave. modified lease and the Pompano Office Lease:

SCHEDULE

OF FUTURE MINIMUM RENTAL PAYMENTS

Years<br> ending March 31, Amount
2022 64,578
2023 259,794
2024 254,050
2025 243,612
2026 248,484
Thereafter 189,144
Total<br> future minimum lease payments 1,259,662
Less:<br> interest (172,307 )
Present<br> value of lease payments $ 1,087,355

The weighted-average remaining lease term and the weighted-average discount rate of our lease was as follows:

SCHEDULE OF WEIGHTED-AVERAGE

REMAINING LEASE TERM AND THE WEIGHTED-AVERAGE DISCOUNT RATE

Lease<br> Term and Discount Rate December<br> 31, 2021
Remaining<br> lease term (years)
Operating<br> leases 7
Discount<br> rate
Operating<br> leases 6 %

The

Company has an obligation for the restoration of its leased facility and the removal or dismantlement of certain property and equipment as a result of its business operation in accordance with ASC 410, Asset Retirement and Environmental Obligations – Asset Retirement Obligations. The Company records the fair value of the asset retirement obligation in the period in which it is incurred. The Company increases, annually, the liability related to this obligation. The liability is accreted to its present value each period and the capitalized cost is depreciated over the useful life of the related asset. Upon settlement of the liability, the Company records either a gain or loss. As of December 31, 2021, and March 31, 2021, the Company had a liability of $38,187 and $37,628, respectively, recorded as a component of other long-term liabilities.

NOTE

  1. PREFERRED STOCK

SeriesJ convertible preferred stock

On

April 28, 2017, the Company created the Series J Convertible Preferred Stock (“Series J Preferred”) in conjunction with the Certificate of Designations (“Series J COD”). A total of 50 shares of Series J Preferred were authorized, zero shares are issued and outstanding, with a stated value of $1,000,000 per share and a par value of $0.01 as of December 31, 2021.

On

April 27, 2017, a total of 24.0344 shares of Series J Preferred were issued pursuant to an exchange agreement (the “Exchange Agreement”) with Hakim, a related party and the Company’s President, Chief Executive Officer and Chairman of the Board of Directors. The Exchange Agreement provided for Hakim to exchange 158,017,321 shares of Common Stock for 24.0344 shares of Series J Preferred and warrants to purchase 79,008,661 shares of Common Stock at $0.1521 per share. The aggregate stated value of the Series J Preferred issued was equal to the aggregate value of the shares of Common Stock exchanged, with such value of each share of Common Stock exchanged being equal to the closing price of the Common Stock on April 27, 2017. In connection with the Exchange Agreement, the Company also issued warrants to purchase 79,008,661 shares of Common Stock at $0.1521 per share, and such warrants are classified as liabilities on the accompanying unaudited condensed consolidated balance sheet as of December 31, 2021 (See Note 11).

| F-17 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

An

amendment to the Company’s Articles of Incorporation to increase the number of shares of Common Stock the Company is authorized to issue from 995,000,000 shares to 1,445,000,000 shares was approved at the Company’s Annual Meeting of Shareholders held on December 4, 2019. Prior to the approval of the increase in the number of authorized shares, there were insufficient authorized shares if the Series J Preferred Stock were converted. As a result, the shares were classified in mezzanine equity. After the approval of the increase in the number of authorized shares, there are now sufficient authorized shares in the event of a full conversion of Series J Preferred Stock. With the approval of the increase in the number of authorized shares, there is no longer the presumption that a cash settlement will be required. Therefore, the Series J Preferred was reclassified from mezzanine equity to permanent equity at its carrying amount of $13,903,960 on the consolidated balance sheet as of March 31, 2020.

On June 23, 2020, the Company held a Special Meeting of Shareholders, with such including a proposal for shareholders to again vote on the above referenced amendment to the Company’s Articles of Incorporation. This proposal was also passed by shareholder vote.

On

August 24, 2020, Hakim converted the 24.0344 shares of Series J Preferred into 158,017,321 shares of Common Stock at a conversion price of $0.1521 per share.

NOTE

  1. DERIVATIVE FINANCIAL INSTRUMENTS – WARRANTS

The Company evaluates and accounts for its freestanding instruments in accordance with ASC 815, Accounting for Derivative Instrumentsand Hedging Activities.

The Company issued warrants, with a term of ten years, to affiliates in connection with an exchange agreement dated April 28, 2017, as further described in this note below.

A summary of warrant activity is as follows:

SCHEDULE OF WARRANT ACTIVITY

December<br> 31, 2021 March<br> 31, 2021
Warrant<br> Shares Weighted<br> Average Exercise Price Warrant<br> Shares Weighted<br> Average Exercise Price
Balance<br> at beginning of period 79,008,661 $ 0.1521 79,008,661 $ 0.1521
Warrants<br> granted pursuant to the issuance of Series J convertible preferred shares — — — —
Warrants<br> exercised, forfeited and/or expired, net — — — —
Balance at end of<br> period 79,008,661 $ 0.1521 79,008,661 $ 0.1521

On

April 28, 2017, the Company entered into an Exchange Agreement with Hakim, the Chairman of the Board, President, and Chief Executive Officer of the Company, pursuant to which the Company issued to Hakim 24.0344 shares of its Series J Preferred and warrants to purchase an aggregate of 79,008,661 shares of its Common Stock (the “Series J Warrants” and, along with the Series J Preferred issued to Hakim, the “Securities”) in exchange for 158,017,321 shares of Common Stock owned by Hakim. The fair value of the Series J Warrants was determined to be $6,474,674 upon issuance at April 28, 2017.

| F-18 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The

Series J Warrants are exercisable for a period of 10 years from the date of issuance, commencing April 28, 2020. The initial exercise price is $0.1521 per share and the Series J Warrants can be exercised for cash or on a cashless basis. The exercise price is subject to adjustment for any issuances or deemed issuances of Common Stock or Common Stock equivalents at an effective price below the then exercise price. Such exercise price adjustment feature prohibits the Company from being able to conclude the warrants are indexed to its own stock and thus such warrants are classified as liabilities and measured initially and subsequently at fair value. The Series J Warrants also provide for other standard adjustments upon the happening of certain customary events.

The fair value of the Series J Warrants was calculated using a Black-Scholes model instead of a Monte Carlo Simulation because the probability with the shareholder approval provisions was no longer a factor. The following assumptions were used in the Black-Scholes model to calculate the fair value of the Series J Warrants:

SCHEDULE

OF FAIR VALUE OF WARRANTS ISSUED

December<br> 31, 2021 March<br> 31, 2021
Fair<br> value of the Company’s Common Stock $ 0.0331 $ 0.0610
Volatility 74.89 % 75.18 %
Initial exercise<br> price $ 0.1521 $ 0.1521
Warrant<br> term (in years) 5.3 6.1
Risk<br> free rate 1.44 % 1.40 %

The changes in warrants (Level 3 financial instruments) measured at fair value on a recurring basis for the nine months ended December 31, 2021 were as follows:

SCHEDULE OF CHANGES IN WARRANTS MEASURED AT FAIR VALUE ON A RECURRING BASIS

Balance<br> at March 31, 2021 $ 2,362,246
Change<br> in fair value of derivative financial instruments - warrants (1,523,394 )
Balance<br> at December 31, 2021 $ 838,852

NOTE

  1. SHAREHOLDERS’ EQUITY

LincolnPark Capital Transaction - July 8, 2020 Purchase Agreement

On

July 8, 2020, the Company entered into a purchase agreement (the “2020 LPC Purchase Agreement”), and a registration rights agreement (the “2020 LPC Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $25.0 million of the Company’s Common Stock, $0.001 par value per share, from time to time over the term of the 2020 LPC Purchase Agreement, at the Company’s direction.

The Company did not issue any shares of its Common Stock pursuant to the 2020 LPC Purchase Agreement during the nine months ended December 31, 2021. In addition, there were no shares issued to Lincoln Park as additional commitment shares, pursuant to the 2020 LPC Agreement.

During

the nine months ended December 31, 2020 the Company issued an aggregate of 5,975,857 shares of Common Stock in the amount of $469,105 to Lincoln Park as initial commitment shares. The Company sold 640,543 shares of its Common Stock pursuant to the 2020 LPC Purchase Agreement during the nine months ended December 31, 2020 for net proceeds totaling $42,223. In addition, 10,094 shares were issued to Lincoln Park as additional commitment shares, pursuant to the 2020 LPC Agreement.

NOTE

  1. STOCK-BASED COMPENSATION

Part of the compensation paid by the Company to its Directors and employees consists of the issuance of Common Stock or via the granting of options to purchase Common Stock.•

Stock-basedDirector Compensation

The Company’s Director compensation policy, instituted in October 2009 and further revised in January 2016, includes provisions that a portion of director’s fees are to be paid via the issuance of shares of the Company’s Common Stock, in lieu of cash, with the valuation of such shares being calculated on quarterly basis and equal to the average closing price of the Company’s Common Stock.

| F-19 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

During

the nine months ended December 31, 2021, the Company issued 886,710 shares of Common Stock to its Directors in payment of director’s fees totaling an aggregate of $60,000 and with such aggregate director’s fees being earned and accrued over the twelve-month period beginning on April 1, 2020 and ending on March 31, 2021. In addition, the Company made cash payments totaling an aggregate of $30,000 in payment of director’s fees earned over the same twelve-month period.

During

the nine months ended December 31, 2021, the Company accrued director’s fees totaling $67,500, which will be paid via cash payments totaling $22,500 and the issuance of 969,319 shares of Common Stock.

As

of December 31, 2021, the Company owed its Directors a total of $22,500 in cash payments and 969,319 shares of Common Stock in payment of director fees totaling $67,500 due and owing. The Company anticipates that these shares of Common Stock will be issued prior to the end of the current fiscal year.

Stock-basedEmployee/Consultant Compensation

Employment contracts with the Company’s President and Chief Executive Officer and certain other employees and engagement contracts with certain consultants include provisions for a portion of each employee’s salaries or consultant’s fees to be paid via the issuance of shares of the Company’s Common Stock, in lieu of cash, with the valuation of such shares being calculated on a quarterly basis and equal to the average closing price of the Company’s Common Stock.

During

the nine months ended December 31, 2021, the Company issued 1,218,526

shares of Common Stock in payment of salaries

totaling $97,500 pursuant to the employment contract of the Company’s former Chief Financial Officer, with such salaries being earned and accrued over the thirty-month period beginning on October 1, 2018 and ending on March 31, 2021.

During

the nine months ended December 31, 2021, the Company accrued salaries totaling $581,250 owed to the Company’s President and Chief Executive Officer and certain other employees which will be paid via the issuance of 12,787,606 shares of Common Stock.

As

of December 31, 2021, the Company owed its President and Chief Executive Officer and certain other employees’ salaries totaling $3,543,750 which will be paid via the issuance of 47,654,194 shares of Common Stock.

During

the nine months ended December 31, 2021, the Company accrued 2,228,004

shares of Common Stock in payment of consulting

fees totaling $153,333 , pursuant to engagement contracts with consultants, and with such consulting expenses being earned and accrued over the forty-eight-month period beginning on January 1, 2018 and ending December 31, 2021.

Options

Under its 2014 Stock Option Plan and prior options plans, the Company may grant stock options to officers, selected employees, as well as members of the Board of Directors and advisory board members. All options have generally been granted at a price equal to or greater than the fair market value of the Company’s Common Stock at the date of the grant. Generally, options are granted with a vesting period of up to three years and expire ten years from the date of grant. A summary of the activity of Company’s 2014 Stock Option Plan for the nine months ended December 31, 2021 is as follows:

| F-20 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

SCHEDULE OF STOCK OPTION PLAN

Shares<br> <br>Underlying<br> <br>Options Weighted<br> <br>Average<br> <br>Exercise Price Weighted Average<br> <br>Remaining Contractual Term (in years) Aggregate Intrinsic<br> <br>Value
Outstanding at March 31, 2021 5,900,000 $ 0.13 3.7 $ 6,000
Forfeited and expired (750,000 ) $ — — —
Granted 300,000 $ 0.06 3.0 —
Outstanding at December 31, 2021 5,450,000 $ 0.14 2.7 $ 6,000
Exercisable at December 31, 2021 5,130,001 $ 0.14 2.7 $ 6,000

The

aggregate intrinsic value for outstanding options is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s Common Stock as of December 31, 2021 and March 31, 2021 of $0.11 and $0.06, respectively.

NOTE

  1. CONCENTRATIONS AND CREDIT RISK

Revenues

Two customers accounted for approximately 96% of the Company’s revenues for the nine months ended December 31, 2021. These two customers accounted for approximately 85% and 11% of revenues each, respectively. The same two customers accounted for 84% and 9% of revenues each, respectively, for the three months ended December 31, 2021.

Two customers accounted for approximately 93% of the Company’s revenues for the nine months ended December 31, 2020. These two customers accounted for approximately 79% and 14% of revenues each, respectively. The same two customers accounted for 82% and 12% of revenues each, respectively, for the three months ended December 31, 2020.

AccountsReceivable

Two customers accounted for approximately 99% of the Company’s accounts receivable as of December 31, 2021. These two customers accounted for approximately 73% and 25% of accounts receivable each, respectively.

Three customers accounted for substantially all the Company’s accounts receivable as of March 31, 2021. These three customers accounted for approximately 73%, 15% and 11% of accounts receivable each, respectively.

Purchasing

Four suppliers accounted for more than 70% of the Company’s purchases of raw materials for the nine months ended December 31, 2021. These four suppliers accounted for approximately 55%, 6%, 5% and 4% of purchases each, respectively.

Four suppliers accounted for more than 81% of the Company’s purchases of raw materials for the nine months ended December 31, 2020. These four suppliers accounted for approximately 59%, 12%, 5%, and 5% of purchases each, respectively.

NOTE

  1. SEGMENT RESULTS

FASB ASC 280-10-50 requires use of the “management approach” model for segment reporting. The management approach is based on the way a company’s management organized segments within the company for making operating decisions and assessing performance. Reportable segments are based on products and services, geography, legal structure, management structure, or any other manner in which management disaggregates a company.

| F-21 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The Company has determined that its reportable segments are ANDAs for generic products and NDAs for branded products. The Company identified its reporting segments based on the marketing authorization relating to each and the financial information used by its chief operating decision maker to make decisions regarding the allocation of resources to and the financial performance of the reporting segments.

Asset information by operating segment is not presented below since the chief operating decision maker does not review this information by segment. The reporting segments follow the same accounting policies used in the preparation of the Company’s unaudited condensed consolidated financial statements.

The following represents selected information for the Company’s reportable segments:

SCHEDULE OF SELECTED INFORMATION FOR REPORTABLE SEGMENTS

2021 2020 2021 2020
For the Three Months Ended December 31, For the Nine Months Ended December 31,
2021 2020 2021 2020
Operating Income by Segment
ANDA $ 3,061,035 $ 2,395,955 8,068,073 6,446,116
NDA — $ (10,972 ) — 142,812
Operating Income by Segment $ 3,061,035 $ 2,384,983 $ 8,068,073 $ 6,588,928

The table below reconciles the Company’s operating income by segment to income from operations before provision for income taxes as reported in the Company’s unaudited condensed consolidated statement of operations:

SCHEDULE OF OPERATING LOSS BY SEGMENT TO (LOSS) INCOME FROM OPERATIONS

2021 2020 2021 2020
For the Three Months Ended December 31, For the Nine Months Ended December 31,
2021 2020 2021 2020
Operating income by segment $ 3,061,035 $ 2,384,983 $ 8,068,073 $ 6,588,928
Corporate unallocated costs (716,881 ) (830,042 ) (2,288,461 ) (1,691,578 )
Interest income 13 98 77 463
Interest expense and amortization of debt issuance costs (37,400 ) (79,673 ) (126,376 ) (238,857 )
Depreciation and amortization expense (296,559 ) (328,899 ) (908,297 ) (990,861 )
Significant non-cash items (216,295 ) (217,900 ) (652,281 ) (686,000 )
Change in fair value of derivative instruments 489,500 1,083,566 1,523,394 1,645,042
Income from operations before income taxes $ 2,283,413 $ 2,012,133 $ 5,616,129 $ 4,627,137

NOTE

  1. RELATED PARTY AGREEMENTS WITH MIKAH PHARMA, LLC

On

December 3, 2018, the Company executed a development agreement with Mikah, pursuant to which Mikah and the Company will collaborate to develop and commercialize generic products including formulation development, analytical method development, bioequivalence studies and manufacture of development batches of generic products. As of March 31, 2021, the Company has incurred costs which are $238,451 in excess of advanced payments received to date from Mikah. This balance due from Mikah was offset, in full, against accrued interest due and owing to Mikah pursuant to the Mikah Note (see Note 7).

In May 2020, SunGen Pharma LLC (“SunGen”), pursuant to an asset purchase agreement, assigned its rights and obligations under the SunGen Agreement for Amphetamine IR and Amphetamine ER to Mikah Pharmaceuticals. The ANDAs for Amphetamine IR and Amphetamine ER are now registered under Elite’s name. Mikah will now be Elite’s partner with respect to Amphetamine IR and ER and will assume all the rights and obligations for these products from SunGen. Mikah Pharmaceuticals was founded in 2009 by Nasrat Hakim, a related party and the Company’s President, Chief Executive Officer and Chairman of the Board.

In June 2021, the Company entered into a development and license agreement with Mikah Pharma LLC, pursuant to which Mikah Pharma LLC will engage in the research, development, sales and licensing of generic pharmaceutical products. In addition, Mikah Pharma LLC will collaborate to develop and commercialize generic products including formulation development, analytical method development, manufacturing, sales and marketing of generic products. Initially two generic products were identified for the parties to develop.

| F-22 |

| --- |

ELITE

PHARMACEUTICALS, INC. AND SUBSIDIARY

NOTES

TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

NOTE

  1. INCOME TAXES

Saleof New Jersey Net Operating Loss

In

April 2020, Elite Labs received final approval from the New Jersey Economic Development Authority for the sale of net tax benefits of $607,635 relating to New Jersey net operating losses and net tax benefits of $338,772, relating to R&D tax credits. The Company sold the net tax benefits approved for sale for total proceeds of $946,407 during the nine months ended December 31, 2020.

Saleof New Jersey Net Operating Loss and Research and Development Tax Credit

In

April 2021, Elite Labs received final approval from the New Jersey Economic Development Authority for the sale of net tax benefits of $796,860 relating to New Jersey net operating losses and net tax benefits of $58,490, relating to research and development tax credits. The Company sold the net tax benefits approved for sale at a transfer price equal to ninety-three- and one-half cents for every benefit dollar and incurred transaction fees of $12,861, resulting in net proceeds to the Company of $857,379, during the nine months ended December 31, 2021.

NOTE

  1. COVID-19 UPDATE

In December 2019, the Novel Corona Virus, COVID-19 was reported to have emerged in Wuhan, China. In March 2020, the World Health Organization (“WHO”) declared the COVID-19 outbreak a global pandemic. Governments at the national, state and local level in the United States, and globally, have implemented aggressive actions to reduce the spread of the virus, with such actions including, without limitation, lockdown and shelter in place orders, limitations on non-essential gatherings of people, suspension of all non-essential travel, and ordering certain businesses and governmental agencies to cease non-essential operations at physical locations. Under current and applicable laws and regulations, the Company’s business is deemed essential, and it has continued to operate in all aspects of its pharmaceutical manufacturing, distribution, product development, regulatory compliance and other activities. The Company’s management has developed and implemented a range of measures to address the risks, uncertainties, and operational challenges associated with operating in a COVID-19 environment. The Company is closely monitoring the rapidly evolving and changing situation and are implementing plans intended to limit the impact of COVID-19 on our business so that the Company can continue to manufacture those medicines used by end user patients. Actions the Company has taken to date are, without limitation, further described below.

Workforce

The Company has taken and will continue to take, proactive measures to provide for the well-being of its workforce while continuing to safely produce pharmaceutical products. The Company has implemented alternative working practices, which include, without limitation, modified schedules, shift rotation and work at home abilities for appropriate employees to best ensure adequate social distancing. In addition, the Company increased its already thorough cleaning protocols throughout its facilities and has prohibited visits from non-essential visitors. Certain of these measures have resulted in increased costs.

Manufacturingand Supply Chain

During the three and nine months ended December 31, 2021, and as of the date of this Quarterly Report on Form 10-Q, the Company has not experienced material, detrimental issues related to COVID-19 in its manufacturing, supply chain, quality assurance and regulatory compliance activities, and has been able to operate without interruption. The Company has taken, and plans to continue to take, commercially practical measures to keep its facilities open. The Company’s supply chains remain intact and operational, and the Company is in regular communications with its suppliers and third-party partners. A prolonging of the current situation relating to COVID-19 may result in an increased risk of interruption in the Company supply chain in the future, with no assurances given as the materiality of such future interruption on the Company’s business, financial condition, results of operations and cash flows.

NOTE

  1. SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through February 11, 2022 and noted no material subsequent events.

| F-23 |

| --- |

ITEM

  1. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Thefollowing discussion of our financial condition and results of operations the three and nine months ended December 31, 2021 and 2020should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that areincluded elsewhere in this report. Our discussion includes forward-looking statements based upon current expectations that involve risksand uncertainties, such as our plans, objectives, expectations and intentions. Actual results and the timing of events could differ materiallyfrom those anticipated in these forward-looking statements as a result of a number of factors, including those set forth under Item 1A.Risk Factors appearing in our Annual Report on Form 10-K for the year ended March 31, 2021. We use words such as “anticipate,”“estimate,” “plan,” “project,” “continuing,” “ongoing,” “expect,”“believe,” “intend,” “may,” “will,” “should,” “could,” and similarexpressions to identify forward-looking statements.

Unlessexpressly indicated or the context requires otherwise, the terms “Elite”, the “Company”, “we”, “us”,and “our” refer to Elite Pharmaceuticals, Inc. and subsidiary.

Background

Elite Pharmaceuticals, Inc., a Nevada corporation (the “Company”, “Elite”, “Elite Pharmaceuticals”, the “registrant”, “we”, “us” or “our”) was incorporated on October 1, 1997 under the laws of the State of Delaware, and its wholly owned subsidiary, Elite Laboratories, Inc. (“Elite Labs”), was incorporated on August 23, 1990 under the laws of the State of Delaware. On January 5, 2012, Elite Pharmaceuticals was reincorporated under the laws of the State of Nevada.

We are a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology for the manufacture of generic pharmaceuticals. Our strategy includes developing generic versions of controlled-release drug products with high barriers to entry.

We occupy manufacturing, warehouse, laboratory and office space at 165 Ludlow Avenue and 135 Ludlow Avenue in Northvale, NJ (the “Northvale Facility”). The Northvale Facility operates under Current Good Manufacturing Practice (“cGMP”) and is a United States Drug Enforcement Agency (“DEA”) registered facility for research, development and manufacturing.

Strategy

We focus our efforts on the following areas: (i) manufacturing of a line of generic pharmaceutical products with approved Abbreviated New Drug Applications (“ANDAs”); (ii) development of additional generic pharmaceutical products; (iii) development of the other products in our pipeline including the products with our partners; (iv) commercial exploitation of our products either by license and the collection of royalties, or through the manufacture of our formulations; and (v) development of new products and the expansion of our licensing agreements with other pharmaceutical companies, including co-development projects, joint ventures and other collaborations.

Our focus is on the development of various types of drug products, including generic drug products which require ANDAs as well as branded drug products which require New Drug Applications (“NDAs”) under Section 505(b)(1) or 505(b)(2) of the Drug Price Competition and Patent Term Restoration Act of 1984 (the “Drug Price Competition Act”).

We believe that our business strategy enables us to reduce its risk by having a diverse product portfolio that includes generic products in various therapeutic categories and to build collaborations and establish licensing agreements with companies with greater resources thereby allowing us to share costs of development and improve cash-flow.

| 1 |

| --- |

CommercialProducts

We own, license, contract manufacture or have contractual rights to receive royalties from the following products currently approved for commercial sale:

Product Branded<br><br> <br>Product<br><br> <br>Equivalent Therapeutic<br><br> <br>Category Launch<br><br> <br>Date
Phentermine<br> HCl 37.5mg tablets (“Phentermine 37.5mg”) Adipex-P® Bariatric April<br> 2011
Phendimetrazine<br> Tartrate 35mg tablets<br><br> <br>(“Phendimetrazine<br> 35mg”) Bontril® Bariatric November<br> 2012
Phentermine<br> HCl 15mg and 30mg capsules<br><br> <br>(“Phentermine<br> 15mg” and “Phentermine 30mg”) Adipex-P® Bariatric April<br> 2013
Naltrexone<br> HCl 50mg tablets<br><br> <br>(“Naltrexone<br> 50mg”) Revia® Addiction<br> Treatment September<br> 2013
Isradipine<br> 2.5mg and 5mg capsules (“Isradipine 2.5mg” and “Isradipine 5mg”) n/a Cardiovascular January<br> 2015
Oxycodone<br> HCl Immediate Release 5mg, 10mg, 15mg, 20mg and 30mg tablets (“OXY IR 5mg”, “Oxy IR 10mg”, “Oxy IR<br> 15mg”, “OXY IR 20mg” and “Oxy IR 30mg”) Roxycodone® Pain March<br> 2016
Trimipramine<br> Maleate Immediate Release 25mg, 50mg and 100mg capsules (“Trimipramine 25mg”, “Trimipramine 50mg”, “Trimipramine<br> 100mg”) Surmontil® Antidepressant May<br> 2017
Dextroamphetamine<br> Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Immediate Release 5mg, 7.5mg, 10mg, 12.5mg, 15mg,<br> 20mg and 30mg tablets (“Amphetamine IR 5mg”, “Amphetamine IR 7.5mg”, “Amphetamine IR 10mg”, “Amphetamine<br> IR 12.5mg”, “Amphetamine IR 15mg”, “Amphetamine IR 20mg” and “Amphetamine IR 30mg”) Adderall® Central<br> Nervous System (“CNS”) Stimulant April<br> 2019
Dantrolene<br> Sodium Capsules 25mg, 50mg and 100mg (“Dantrolene 25mg”, “Dantrolene 50mg”, “Dantrolene 100mg”) Dantrium® Muscle<br> Relaxant June<br> 2019
Dextroamphetamine<br> Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release 5mg, 10mg, 15mg, 20mg, 25mg, and<br> 30mg capsules (“Amphetamine ER 5mg”, “Amphetamine ER 10mg”, “Amphetamine ER 15mg”, “Amphetamine<br> ER 20mg”, “Amphetamine ER 25mg”, and “Amphetamine ER 30mg”) Adderall<br> XR® Central<br> Nervous System (“CNS”) Stimulant March<br> 2020
Loxapine<br> Succinate 5mg, 10mg, 25mg and 50gm capsules (“Loxapine 5mg”, “Loxapine 10mg”, “Loxapine 25mg”,<br> and Loxapine 50mg”) Loxapine® Antipsychotic May<br> 2021

ApprovedProducts Not Yet Commercialized

Acetaminophenand Codeine Phosphate

The Company received approval from the FDA of an ANDA for a generic version of Tylenol® with Codeine (acetaminophen and codeine phosphate). Acetaminophen with codeine is a combination medication indicated for the management of mild to moderate pain, where treatment with an opioid is appropriate and for which alternative treatments are inadequate. The Company is not pursuing licensing deals for any opioids at this time and, in light of the current market and litigation around opioid products, the Company has no plans to commercialize this product at this time.

CriticalAccounting Policies and Estimates

The preparation of the unaudited condensed consolidated financial statements and related disclosures in conformity with GAAP, and our discussion and analysis of its financial condition and operating results require our management to make judgments, assumptions and estimates that affect the amounts reported in its unaudited condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on various other assumptions it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results may differ from these estimates and such differences may be material.

| 2 |

| --- |

There were no significant changes during the three months ended December 31, 2021 to the items that we disclosed as our significant accounting policies and estimates described in “Note 1, Summary of Significant Accounting Policies” to the Company’s financial statements as contained in the Company’s Annual Report on Form 10-K for the fiscal year ended March 31, 2021.

Resultsof Operations

The following set forth our results of operations for the periods presented. The period-to-period comparison of financial results is not necessarily indicative of future results.

Threemonths ended December 31, 2021 compared to December 31, 2020

Revenue,Cost of revenue and Gross profit:

For the Three Months Ended December 31, Change
2021 2020 Dollars Percentage
Manufacturing fees $ 7,667,674 $ 4,849,871 $ 2,817,803 58 %
Licensing fees 1,307,140 1,196,711 110,429 9 %
Total revenue 8,974,814 6,046,582 2,928,232 48 %
Cost of manufacturing 4,957,150 2,643,175 2,313,975 88 %
Gross profit $ 4,017,664 $ 3,403,407 $ 614,257 18 %
Gross profit - percentage 45 % 56 %

Total revenues for the three-month period ended December 31, 2021 increased by $3 million or 48%, to $9.0 million, as compared to $6.0 million, for the corresponding period of the prior year, primarily due to strong sales of Amphetamine IR and ER tablets during the three-month period ended December 31, 2021 as compared to the comparable period of the prior fiscal year.

Manufacturing fees increased by $2.8 million, or 58%, primarily due to strong sales of Amphetamine IR and ER tablets during the three-month period ended December 31, 2021 as compared to the comparable period of the prior fiscal year.

Licensing fees increased by $0.1 million, or 9%. This increase is primarily due to strong sales of Amphetamine IR and ER tablets during the three months ended December 31, 2021 as compared to the comparable period of the prior fiscal year.

Costs of revenue consists of manufacturing and assembly costs. Our costs of revenue increased by $2.3 million or 88%, to $4.9 million as compared to $2.6 million for the corresponding period in the prior fiscal year. This increase was due to higher revenues during the three months ended December 31, 2021, as compared to the comparable period of the prior fiscal year.

Our gross profit margin was 45% during the three months ended December 31, 2021 as compared to 56% during the comparable period of the prior fiscal year.

| 3 |

| --- |

Operatingexpenses:

For the Three Months Ended December 31, Change
2021 2020 Dollars Percentage
Operating expenses:
Research and development $ 956,628 $ 1,245,669 $ (289,041 ) (23 )%
General and administrative 929,547 826,019 103,528 13 %
Non-cash compensation 3,630 1,651 1,979 120 %
Depreciation and amortization 296,559 328,899 (32,340 ) (10 )%
Total operating expenses $ 2,186,364 $ 2,402,238 $ (215,874 ) (9 )%

Operating expenses consist of research and development costs, general and administrative, non-cash compensation and depreciation and amortization expenses. Operating expenses for the three months ended December 31, 2021 decreased by $0.2 million, or 9%, to $2.2 million as compared to $2.4 million for the corresponding period in the prior fiscal year.

Research and development costs for the three months ended December 31, 2021 were $0.9 million, a decrease of $0.3 million, or 23%, from $1.2 million of such costs for the comparable period of the prior year.

General and administrative expenses for the three months ended December 31, 2021 were $0.9 million, an increase of $0.1 million or 13% from $0.8 million of such costs for the comparable period of the prior year.

Non-cash compensation expense for the three months ended December 31, 2021 and 2020 was less than $0.1 million.

Depreciation and amortization expenses for the three months ended December 31, 2021 were $0.3 million, which remained consistent from $0.3 million of such costs for the comparable period of the prior fiscal year.

As a result of the foregoing, our income from operations for the three months ended December 31, 2021 was $1.8 million, compared to income from operations of $1.0 million for the comparable period of the prior fiscal year.

Otherincome, net:

For the Three Months Ended December 31, Change
2021 2020 Dollars Percentage
Other income, net:
Change in fair value of derivative instruments $ 489,500 $ 1,083,566 $ (594,066 ) (55 )%
Interest expense and amortization of debt issuance costs (37,400 ) (79,673 ) 42,273 (53 )%
Gain on sale of fixed assets — 6,973 (6,973 ) (100 )%
Interest income 13 98 (85 ) (87 )%
Other income, net $ 452,113 $ 1,010,964 $ (558,851 ) (55 )%

Other income, net for the three months ended December 31, 2021 was $0.5 million, a decrease of $0.6 million from the other income, net of $1.0 million for the comparable period of the prior fiscal year. The decrease in other income was due to income relating to changes in the fair value of our outstanding derivative warrants during the three months ended December 31, 2021. Please note that the change in the fair value of derivative instruments is determined in large part by the change in the closing price of the Company’s Common Stock as of the end of the period, as compared to the closing price at the beginning of the period, with a strong inverse relationship between the fair value of our derivatives instruments and decreases in the closing price of the Company’s Common Stock. Please see Note 11 to the Unaudited Condensed Consolidated Financial Statements above.

| 4 |

| --- |

As a result of the foregoing, our net income before the net benefit from sale of net operating loss credits for the three months ended December 31, 2021 was $2.3 million, compared to net income of $2.0 million for the comparable period of the prior fiscal year.

Ninemonths ended December 31, 2021 compared to December 31, 2020

Revenue,Cost of revenue and Gross profit:

For the Nine Months Ended December 31, Change
2021 2020 Dollars Percentage
Manufacturing fees $ 20,639,421 $ 17,659,834 $ 2,979,587 17 %
Licensing fees 3,950,623 3,325,384 625,239 19 %
Total revenue 24,590,044 20,985,218 3,604,826 17 %
Cost of manufacturing 13,209,430 10,984,021 2,225,409 20 %
Gross profit $ 11,380,614 $ 10,001,197 $ 1,379,417 14 %
Gross profit - percentage 46 % 48 %

Total revenues for the nine-month period ended December 31, 2021 increased by $3.6 million or 17%, to $24.6 million, as compared to $21.0 million, for the corresponding period of the prior year, primarily due strong sales of Amphetamine IR and ER tablets during the nine-month period ended December 31, 2021 as compared to the comparable period of the prior fiscal year.

Manufacturing fees for the nine-month period ended December 31, 2021 were $20.6 million, an increase of $2.9 million, or 17%, from $17.7 million primarily due to strong sales of Amphetamine IR and ER tablets during the nine months ended December 31, 2021 as compared to the comparable period of the prior year.

Licensing fees increased by $0.6 million, or 19%. This increase is primarily due to strong sales of Amphetamine IR and ER tablets during the nine months ended December 31, 2021 as compared to the comparable period of the prior fiscal year.

Costs of revenue consists of manufacturing and assembly costs. Our costs of revenue for the nine-month period ended December 31, 2021 were $13.2 million, an increase of $2.2 million, or 20%, from $11.0 million of such fees for the comparable period of the prior year.

Our gross profit margin was 46% during the nine months ended December 31, 2021 as compared to 48% during the comparable period of the prior fiscal year.

| 5 |

| --- |

Operatingexpenses:

For the Nine Months Ended December 31, Change
2021 2020 Dollars Percentage
Operating expenses:
Research and development $ 3,312,540 $ 3,337,287 $ (24,747 ) (1 )%
General and administrative 2,930,126 2,491,762 438,364 18 %
Non-cash compensation 10,617 9,261 1,356 15 %
Depreciation and amortization 908,297 990,861 (82,564 ) (8 )%
Total operating expenses $ 7,161,580 $ 6,829,171 $ 332,409 5 %

Operating expenses consist of research and development costs, general and administrative, non-cash compensation and depreciation and amortization expenses. Operating expenses for the nine months ended December 31, 2021 increased by $0.3 million, or 5%, to $7.1 million as compared to $6.8 million for the corresponding period in the prior fiscal year.

Research and development costs for the nine months ended December 31, 2021 were $3.3 million, which was virtually unchanged from approximately $3.3 million of such costs for the comparable period of the prior year.

General and administrative expenses for the nine months ended December 31, 2021 were $2.9 million, an increase of $0.4 million, or 18% from $2.5 million of such costs for the comparable period of the prior year due to increased costs and headcounts relating to regulatory compliance and laboratory activities.

Non-cash compensation expense for the nine months ended December 31, 2021 and 2020 was less than $0.1 million.

Depreciation and amortization expenses for the nine months ended December 31, 2021 were $0.9 million, which was virtually unchanged from $1.0 million in such costs for the comparable period of the prior fiscal year.

As a result of the foregoing, our income from operations for the nine months ended December 31, 2021 was $4.2 million, compared to income from operations of $3.2 million for the comparable period of the prior fiscal year.

| 6 |

| --- |

Otherincome, net:

For the Nine Months Ended December 31, Change
2021 2020 Dollars Percentage
Other income, net:
Change in fair value of derivative instruments $ 1,523,394 $ 1,645,042 $ (121,648 ) (7 )%
Interest expense and amortization of debt issuance costs (126,376 ) (238,857 ) 112,481 47 %
Gain on sale of fixed assets — 48,463 (48,463 ) (100 )%
Interest income 77 463 (386 ) (83 )%
Other income, net $ 1,397,095 $ 1,455,111 $ (58,016 ) (4 )%

Other income, net for the nine months ended December 31, 2021 was $1.4 million, a decrease of $0.1 million from the other income, net of $1.5 million for the comparable period of the prior fiscal year. The decrease in other income was due to income relating to changes in the fair value of our outstanding derivative warrants during the nine-month period ended December 31, 2021. Please note that the change in the fair value of derivative instruments is determined in large part by the change in the closing price of the Company’s Common Stock as of the end of the period, as compared to the closing price at the beginning of the period, with a strong inverse relationship between the fair value of our derivatives instruments and decreases in the closing price of the Company’s Common Stock. Please see Note 11 to the Unaudited Condensed Consolidated Financial Statements above.

As a result of the foregoing, our net income before the net benefit from sale of net operating loss credits for the nine months ended December 31, 2021 was $5.6 million, compared to net income $4.6 million for the comparable period of the prior fiscal year.

Liquidityand Capital Resources

CapitalResources

December 31, 2021 March 31, 2021 Change
Current assets $ 17,475,013 $ 12,194,667 $ 5,280,346
Current liabilities $ 5,878,203 $ 5,812,531 $ 65,672
Working capital $ 11,596,810 $ 6,382,136 $ 5,214,674

Our working capital (total current assets less total current liabilities) increased by $5.2 million from $6.4 million as of March 31, 2021 to $11.6 million as of December 31, 2021, with such increase being primarily related to the net income of $6.5 million and a net positive cash flow of $4.1 million achieved during the nine months ended December 31, 2021.

Summaryof Cash Flows:

For the Nine Months Ended December 31,
2021 2020
Net cash provided by operating activities $ 4,902,978 $ 3,943,229
Net cash used in investing activities $ (234,387 ) $ (77,879 )
Net cash (used in) provided by financing activities $ (572,889 ) $ 415,910

Net cash provided by operating activities for the nine months ended December 31, 2021 was $4.9 million, which included net income of $6.5 million and increases in non-cash expenses totaling $0.2 million, offset by net increases in assets and decreases in liabilities totaling $(1.8) million.

Net cash used in investing activities for the nine months ended December 31, 2021 was comprised of purchases of property and equipment of $0.2 million.

| 7 |

| --- |

Net cash used in financing activities was $0.6 million for the nine months ended December 31, 2021 which consisted of loan and bond payments.

LincolnPark Capital – July 8, 2020 Purchase Agreement

On July 8, 2020, the Company entered into a purchase agreement (the “2020 LPC Purchase Agreement”), and a registration rights agreement, with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $25.0 million of the Company’s Common Stock, $0.001 par value per share, from time to time over the term of the 2020 LPC Purchase Agreement, at the Company’s direction.

The Company did not issue any shares of its Common Stock pursuant to the 2020 LPC Purchase Agreement during the nine months ended December 31, 2021. In addition, there were no shares issued to Lincoln Park as additional commitment shares, pursuant to the 2020 LPC Agreement.

During the nine months ended December 31, 2020 the Company issued an aggregate of 5,975,857 shares of Common Stock in the amount of $469,105 to Lincoln Park as initial commitment shares. The Company sold 640,543 shares of its Common Stock pursuant to the 2020 LPC Purchase Agreement during the nine months ended December 31, 2020 for net proceeds totaling $42,223. In addition, 10,094 shares were issued to Lincoln Park as additional commitment shares, pursuant to the 2020 LPC Agreement for net proceeds totaling $732.

ITEM

  1. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide the information required by this Item.

ITEM

  1. CONTROLS AND PROCEDURES

Evaluationof Disclosure Controls and Procedures

The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act, refers to controls and procedures that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. As required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act, our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective as of June 30, 2021 at the reasonable assurance level.

Management’sReport on Internal Control Over Financial Reporting

Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that:(1) pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company’s assets that could have a material effect on the financial statements.

| 8 |

| --- |

Internal control over financial reporting may not prevent or detect all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of internal control, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our systems of controls to enhance, where necessary, our control policies and procedures.

Management is responsible for establishing and maintaining adequate internal control over our financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting. Management has used the framework set forth in the report entitled “Internal Control—Integrated Framework (2013)” published by the Committee of Sponsoring Organizations of the Treadway Commission to evaluate the effectiveness of our internal control over financial reporting. Based on its evaluation, management has concluded that our internal control over financial reporting was effective as of December 31, 2021 at the reasonable assurance level.

Changesin Internal Controls Over Financial Reporting

There were no changes, subsequent to those identified in our Annual Report on Form 10-K for the fiscal year ended March 31, 2021 filed with the SEC on June 15, 2021, in our internal control over financial reporting (as defined in Rule 13a-15(f) and Rule 15d-15(f) under the Exchange Act) during the end of the period covered by this Quarterly Report.

| 9 |

| --- |

PART

II - OTHER INFORMATION

ITEM

  1. LEGAL PROCEEDINGS

PendingLitigation

We may be subject from time to time to various claims and legal actions arising during the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations, financial condition or cash flows.

ITEM

1A. RISK FACTORS

There have been no material changes in the risk factors described in our Annual Report on Form 10-K for the year ended March 31, 2021.

ITEM

  1. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM

  1. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM

  1. MINE SAFETY DISCLOSURES

Not applicable.

ITEM

  1. OTHER INFORMATION

None.

| 10 |

| --- |

ITEM

  1. EXHIBITS
Exhibit<br><br> <br>No. Description
31.1 Certification<br> of Chief Executive Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
31.2 Certification<br> of Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a) and Rule 15d-14(a)*
32.1 Certification<br> of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
32.2 Certification<br> of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*
101.INS Inline<br> XBRL Instance Document
101.SCH Inline<br> XBRL Taxonomy Schema Document
101.CAL Inline<br> XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF Inline<br> XBRL Taxonomy Extension Definition Linkbase Document
101.LAB Inline<br> XBRL Taxonomy Extension Label Linkbase Document
101.PRE Inline<br> XBRL Taxonomy Extension Presentation Linkbase Document
104 Cover<br> Page Interactive Data File (embedded within the Inline XBRL document)
* Filed<br> herewith.
--- ---
** Furnished<br> herewith. 
| 11 |

| --- |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ELITE PHARMACEUTICALS, INC.
February<br> 14, 2022 By: /s/ Nasrat Hakim
Nasrat<br> Hakim<br><br> <br>Chief<br> Executive Officer, President and<br><br> <br>Chairman<br> of the Board of Directors<br><br> <br>(Principal<br> Executive Officer)
February<br> 14, 2022 By: /s/ Marc Bregman
Marc<br> Bregman<br><br> <br>Chief<br> Financial Officer, Treasurer and Secretary<br><br> <br>(Principal<br> Financial and Accounting Officer) 
| 12 |

| --- |

Exhibit31.1

CERTIFICATIONBY PRINCIPAL EXECUTIVE OFFICER

I, Nasrat Hakim, certify that:

1. I<br> have reviewed this Quarterly Report on Form 10-Q for the quarter ended December 31, 2021 of Elite Pharmaceuticals, Inc. (the “Registrant”)
2. Based<br> on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary<br> to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to<br> the period covered by this report;
3. Based<br> on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material<br> respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in<br> this report;
4. The<br> Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures<br> (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange<br> Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have:
a. Designed<br> such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,<br> to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others<br> within those entities, particularly during the period in which this report is being prepared;
--- ---
b. Designed<br> such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our<br> supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements<br> for external purposes in accordance with generally accepted accounting principles;
c. Evaluated<br> the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about<br> the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation;<br> and
d. Disclosed<br> in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s<br> most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected,<br> or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting.
5. The<br> Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial<br> reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing<br> the equivalent functions):
--- ---
a. All<br> significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are<br> reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information;<br> and
--- ---
b. Any<br> fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s<br> internal control over financial reporting.
Date:<br> February 14, 2022 /s/ Nasrat Hakim
--- ---
Nasrat<br> Hakim<br><br> <br>Chief<br> Executive Officer, President and Chairman of the Board of Directors<br><br> <br>(Principal<br> Executive Officer)

Exhibit 31.2

CERTIFICATION BY PRINCIPAL FINANCIAL OFFICER

I, Marc Bregman, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q for the quarter ended December 31, 2021 of Elite Pharmaceuticals, Inc. (the “Registrant”)
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the periods covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The Registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Registrant and have :
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
--- ---
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the Registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the Registrant’s internal control over financial reporting that occurred during the Registrant’s most recent fiscal quarter (the Registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Registrant’s internal control over financial reporting.
5. The<br> Registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial<br> reporting, to the Registrant’s auditors and the audit committee of the Registrant’s board of directors (or persons performing<br> the equivalent functions):
--- ---
a. All<br> significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are<br> reasonably likely to adversely affect the Registrant’s ability to record, process, summarize and report financial information;<br> and
--- ---
b. Any<br> fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant’s<br> internal control over financial reporting.
Date: February 14, 2022 /s/ Marc Bregman
--- ---
Marc Bregman<br><br> <br>Chief Financial Officer, Treasurer and Secretary<br><br> <br>(Principal Accounting and Financial Officer)

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Elite Pharmaceuticals, Inc. (the “Registrant”) on Form 10-Q for the quarter ended December 31, 2021 filed with the Securities and Exchange Commission (the “Report”), I, Nasrat Hakim, Chief Executive Officer of the Registrant, certify, pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

Information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: February 14, 2022 /s/ Nasrat Hakim
Nasrat Hakim<br><br> <br>Chief Executive Officer, President and Chairman of<br> the Board of Directors<br><br> <br>(Principal Executive Officer)

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Elite Pharmaceuticals, Inc. (the “Registrant”) on Form 10-Q for the quarter ended December 31, 2021 filed with the Securities and Exchange Commission (the “Report”), I, Marc Bregman, Chief Financial Officer and Treasurer of the Registrant, certify, pursuant to 18 U.S. C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

Information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: February 14, 2022 /s/ Marc Bregman
Marc Bregman<br><br> <br>Chief Financial Officer, Treasurer and Secretary<br><br> <br>(Principal Accounting and Financial Officer)

This certification has been furnished solely pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

A signed original of this written statement required by Section 906 has been provided to Elite Pharmaceuticals, Inc. and will be retained by Elite Pharmaceuticals Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

Report a Problem

Category
Description
Email (optional, for follow-up)